United Therapeutics (NASDAQ:UTHR) Director Sells $115,338.36 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 228 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the sale, the director owned 5,580 shares in the company, valued at $2,822,754.60. The trade was a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $497.27 on Friday. The stock has a market capitalization of $21.33 billion, a price-to-earnings ratio of 17.79, a PEG ratio of 2.50 and a beta of 0.56. United Therapeutics Corporation has a 1-year low of $402.50 and a 1-year high of $609.35. The company has a 50 day moving average price of $516.53 and a 200 day moving average price of $540.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.41 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Arjuna Capital boosted its stake in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC increased its position in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.